| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/31/2023 | 589.66% | HC Wainwright & Co. | $7 → $10 | Maintains | Buy |
| 05/03/2021 | 382.76% | HC Wainwright & Co. | $11 → $7 | Maintains | Buy |
| 06/08/2020 | 658.62% | HC Wainwright & Co. | $3 → $11 | Maintains | Buy |
What is the target price for Protalix BioTherapeutics (PLX)?
The latest price target for Protalix BioTherapeutics (AMEX: PLX) was reported by HC Wainwright & Co. on October 31, 2023. The analyst firm set a price target for $10.00 expecting PLX to rise to within 12 months (a possible 589.66% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Protalix BioTherapeutics (PLX)?
The latest analyst rating for Protalix BioTherapeutics (AMEX: PLX) was provided by HC Wainwright & Co., and Protalix BioTherapeutics maintained their buy rating.
When is the next analyst rating going to be posted or updated for Protalix BioTherapeutics (PLX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Protalix BioTherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Protalix BioTherapeutics was filed on October 31, 2023 so you should expect the next rating to be made available sometime around October 31, 2024.
Is the Analyst Rating Protalix BioTherapeutics (PLX) correct?
While ratings are subjective and will change, the latest Protalix BioTherapeutics (PLX) rating was a maintained with a price target of $7.00 to $10.00. The current price Protalix BioTherapeutics (PLX) is trading at is $1.45, which is out of the analyst's predicted range.